JonesTrading analyst Soumit Roy reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Tuesday, setting a price target of $110, which is approximately 97.10% above the present share price of $55.81.
Roy expects Cassava Sciences to post earnings per share (EPS) of -$0.06 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Cassava Sciences, with an average price target of $89.75.
The analysts price targets range from a high of $110 to a low of $72.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$1.44 million. The company's market cap is $2.18 billion.
According to TipRanks.com, JonesTrading analyst Soumit Roy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 62.0% and a 58.26% success rate.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.